Quest Diagnostics Incorporated
DGXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. At a $23.32B market cap, Quest Diagnostics Incorporated ranks as a large-cap company within healthcare. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Market Cap
$23.32B
Beta
0.57
P/E (TTM)
23.15
P/E (Fwd)
18.05
EPS (TTM)
$9.10
EPS (Fwd)
$11.67
ROE
14.5%
ROA
6.3%
Cash
$393.0M
Total Debt
$6.41B
Free CF
$947.9M
52W Change
26.2%
Annual Financials
Cash vs Debt
The company holds $393.0M in cash, though total debt stands at $6.41B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $947.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 14.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $9.88B to $11.04B.
The relatively low beta of 0.57 suggests DGX is a less volatile holding compared to the broader index. Quest Diagnostics Incorporated carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DGX.